Elevance Health downgraded by BofA Securities with a new price target
$ELV
Medical Specialities
Health Care
BofA Securities downgraded Elevance Health from Buy to Neutral and set a new price target of $530.00 from $646.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/18/2024 | Buy → Hold | Argus | |
| 7/18/2024 | $646.00 → $530.00 | Buy → Neutral | BofA Securities |
| 6/24/2024 | $643.00 | Overweight | Morgan Stanley |
| 5/30/2024 | $649.00 | Outperform | Robert W. Baird |
| 3/6/2024 | $584.00 | Overweight | Barclays |
| 7/12/2023 | Outperform → Peer Perform | Wolfe Research | |
| 4/27/2023 | $500.00 → $571.00 | Equal-Weight → Overweight | Morgan Stanley |
| 4/21/2023 | $547.00 | Overweight | Cantor Fitzgerald |
Elevance Health (NYSE:ELV) announced today that senior management is scheduled to present at the UBS Global Healthcare Conference in Rancho Palos Verdes, California on November 12, at 7:15 a.m. Pacific Standard Time (PST) / 10:15 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the "Investors" link. You may also access the link here. For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation. To listen to the live webcast, please visit Elevance Health's website www.elevancehealth.com at least 15 minutes early to downloa
Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe
Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l
Elevance Health's (NYSE:ELV) short percent of float has fallen 4.08% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 0.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.45 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interes
Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.
Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $600 to $593.
3Q 2024 operating revenue of $44.7 billion 3Q 2024 adjusted operating gain1 of $2.4 billion 3Q 2024 diluted EPS2 of $4.36; adjusted diluted EPS1 of $8.37 4Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported third quarter 2024 results. "We remain confident in the long-term earnings potential of our diverse businesses as we navigate a dynamic operating environment and unprecedented challenges in the Medicaid business. We expect Medicaid rates will align with the needs of our members in time, and are taking proactive actions to enhance operational efficiencies that will ensure we emerge from this period even stronger." Gail K. Boudre
Elevance Health (NYSE:ELV) will release third quarter 2024 financial results on October 17, 2024, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers: 888-947-9963 – Access Code - 3972058 (Domestic) 312-470-0178 – Access Code - 3972058 (International) 866-510-4837 – No Access Code (Domestic Replay) 203-369-1943 – No Access Code (International Replay) The replay will be available from 11:30 a.m. EDT on October 17, 2024, until the end of the day on November 16, 2024. The call
2Q 2024 operating revenue of $43.2 billion 2Q 2024 adjusted operating gain1 of $2.8 billion 2Q 2024 diluted EPS2 of $9.85, up 26%; adjusted diluted EPS1 of $10.12, up 12% 3Q 2024 dividend of $1.63 per share declared to shareholders Elevance Health, Inc. (NYSE:ELV) reported second quarter 2024 results. "Second quarter results reflect the power of our diversified business and thoughtful execution of our strategic initiatives during a dynamic time for our industry, as we remain steadfast in our purpose to improve the health of humanity. We have prudently maintained our full-year outlook and are confident in the earnings power of our Health Benefits and Carelon businesses, which
SC 13G/A - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
SC 13G - Elevance Health, Inc. (0001156039) (Subject)
Argus downgraded Elevance Health from Buy to Hold
BofA Securities downgraded Elevance Health from Buy to Neutral and set a new price target of $530.00 from $646.00 previously
Morgan Stanley initiated coverage of Elevance Health with a rating of Overweight and set a new price target of $643.00
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
4 - Elevance Health, Inc. (0001156039) (Issuer)
8-K - Elevance Health, Inc. (0001156039) (Filer)
424B3 - Elevance Health, Inc. (0001156039) (Filer)
FWP - Elevance Health, Inc. (0001156039) (Subject)
Elevance Health (NYSE:ELV) announced today the appointment of Nathan Rich as Vice President, Investor Relations, effective November 11, 2024. In this role, Mr. Rich will lead Elevance Health's investor relations efforts, providing strategic leadership to support the company's growth initiatives and strengthen relationships within the investment community. He will also serve as a member of the company's executive leadership team and will report directly to Mark Kaye, Executive Vice President and Chief Financial Officer. Mr. Rich succeeds Stephen Tanal, who now serves as Chief Financial Officer for Elevance Health's Government Health Benefits business. "Nate brings nearly two decades of expe
Nationally Recognized Healthcare Policy Leader Adam Herbst Strengthens the Firm's Regulatory Capabilities for Clients Across the Post-Acute, Aging and Long-Term Care Sectors Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Adam S. Herbst has joined the firm as a healthcare partner in New York. Most recently, Herbst served as the New York State Department of Health's Deputy Commissioner for Aging and Long Term Care. He is the ninth healthcare partner to join the firm in 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241030758975/en/Adam Herbst (Photo: Business Wire) In joining Sheppard Mullin's industry-l
Performant Financial Corporation (NASDAQ:PFMT) (Performant), primarily operating as Performant Healthcare Solutions, a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, is proud to announce the appointment of Dr. Shantanu Agrawal, M.D. to its Board of Directors. Dr. Agrawal brings a wealth of expertise and experience in healthcare policy and payment integrity. As Chief Health Officer at Elevance Health (NYSE:ELV), Dr. Agrawal oversees the whole health strategy, including medical policy and clinical quality, as well as the community health strategy and Elevance Health Foundation. Prior to Elevance Health, Dr. Agrawal held numerous execut